Literature DB >> 11836323

A new recombinant cell bioassay for ultrasensitive determination of serum estrogenic bioactivity in children.

Françoise Paris1, Nadège Servant, Béatrice Térouanne, Patrick Balaguer, Jean Claude Nicolas, Charles Sultan.   

Abstract

The evaluation of estrogenic status is necessary for many physiological and pathological conditions in pediatric as well as adult endocrinology. Because current immunoassays exclusively measure E2--and with a sensitivity that is insufficient for prepubertal children--we developed a new recombinant cell bioassay for ultrasensitive determination of serum estrogenic bioactivity. This assay is based on human uterine cervix carcinoma cells, HeLa cells, that do not naturally express E2 receptor. These cells were transfected with plasmids encoding the human ERalpha or beta, along with an estrogen-responsive promoter fused to the luciferase gene, and called HELNalpha and HELNbeta for HeLa estrogen-responsive element luciferase neomycin alpha and beta. HELNalpha and HELNbeta are able to respond to estrogens and various compounds having estrogenic activity but, because of the importance of ERalpha in the reproductive function, we chose to work with the HELNalpha cell line. The luciferase activity we obtained was compared with an E2 standard curve specific for each serum sample and established with stripped serum. The estrogenic bioactivity was expressed in picograms of E2 equivalents, and the detection limit was < 1 pg x ml(-1) E2 equivalents. The intra and interassay error was lower than 10% and 20%, respectively. We measured estrogenic bioactivity in 18 normal prepubertal boys (age = 9.7 +/- 2.4 yr), 18 normal prepubertal girls (age = 9.2 +/- 1.7 yr) and 18 normal pubertal girls (age = 13.6 +/- 1.8 yr). The estrogenic bioactivity in the prepubertal girls was significantly higher than in the boys, i.e. 3.53 +/- 2.23 pg x ml(-1) vs. 1.44 +/- 0.87 pg x ml(-1) (P < 0.01). A significant difference was found between the pre- and pubertal girls, i.e. 3.53 +/- 2.23 pg x ml(-1) vs. 26.77 +/- 18.32 pg x ml(-1) (P < 0.01). This ultrasensitive bioassay measures total estrogenic bioactivity of serum with very high sensitivity. It has numerous potential applications in pediatric and adult endocrinology. In addition, this assay may help to evaluate excess estrogenic activity related to aromatase overexpression or contamination by environmental chemicals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836323     DOI: 10.1210/jcem.87.2.8269

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Hormone changes in peripubertal girls.

Authors:  Frank M Biro; Susan M Pinney; Bin Huang; Erin R Baker; Donald Walt Chandler; Lorah D Dorn
Journal:  J Clin Endocrinol Metab       Date:  2014-07-16       Impact factor: 5.958

2.  Serum free estradiol and estrogen receptor-α mediated activity are related to decreased incident hip fractures in older women.

Authors:  Vanessa W Lim; Jun Li; Yinhan Gong; Jian-Min Yuan; Tsung Sheng Wu; Geoffrey L Hammond; Aizhen Jin; Woon-Puay Koh; E L Yong
Journal:  Bone       Date:  2012-03-16       Impact factor: 4.398

Review 3.  The androgen receptor and its use in biological assays: looking toward effect-based testing and its applications.

Authors:  Amy B Cadwallader; Carol S Lim; Douglas E Rollins; Francesco Botrè
Journal:  J Anal Toxicol       Date:  2011-11       Impact factor: 3.367

Review 4.  Expression of the IGF and the aromatase/estrogen receptor systems in human adrenal tissues from early infancy to late puberty: implications for the development of adrenarche.

Authors:  Alicia Belgorosky; María Sonia Baquedano; Gabriela Guercio; Marco A Rivarola
Journal:  Rev Endocr Metab Disord       Date:  2009-03       Impact factor: 6.514

5.  Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women.

Authors:  Evangelia-Ourania Fourkala; Alexey Zaikin; Matthew Burnell; Aleksandra Gentry-Maharaj; Jeremy Ford; Richard Gunu; Christina Soromani; Guido Hasenbrink; Ian Jacobs; Anne Dawnay; Martin Widschwendter; Hella Lichtenberg-Fraté; Usha Menon
Journal:  Endocr Relat Cancer       Date:  2012-04-10       Impact factor: 5.678

6.  Sex-specific Estrogen Levels and Reference Intervals from Infancy to Late Adulthood Determined by LC-MS/MS.

Authors:  Hanne Frederiksen; Trine Holm Johannsen; Stine Ehlern Andersen; Jakob Albrethsen; Selma Kløve Landersoe; Jørgen Holm Petersen; Anders Nyboe Andersen; Esben Thyssen Vestergaard; Mia Elbek Schorring; Allan Linneberg; Katharina M Main; Anna-Maria Andersson; Anders Juul
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

7.  Serum oestrogen receptor alpha and beta bioactivity are independently associated with breast cancer: a proof of principle study.

Authors:  M Widschwendter; H Lichtenberg-Frate; G Hasenbrink; S Schwarzer; A Dawnay; A Lam; U Menon; S Apostolidou; E Raum; C Stegmaier; I J Jacobs; H Brenner
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

8.  An information-theoretic analysis of genetics, gender and age in cancer patients.

Authors:  Gurinder Singh Atwal; Raúl Rabadán; Guillermina Lozano; Louise C Strong; Mariëlle W G Ruijs; Marjanka K Schmidt; Laura J van't Veer; Heli Nevanlinna; Johanna Tommiska; Kristiina Aittomäki; Gaelle Bougeard; Thierry Frebourg; Arnold J Levine; Gareth L Bond
Journal:  PLoS One       Date:  2008-04-09       Impact factor: 3.240

9.  Twenty-four hours secretion pattern of serum estradiol in healthy prepubertal and pubertal boys as determined by a validated ultra-sensitive extraction RIA.

Authors:  Carina Ankarberg-Lindgren; Ensio Norjavaara
Journal:  BMC Endocr Disord       Date:  2008-09-25       Impact factor: 2.763

Review 10.  The Effect of Bisphenol A on Puberty: A Critical Review of the Medical Literature.

Authors:  Alberto Leonardi; Marta Cofini; Donato Rigante; Laura Lucchetti; Clelia Cipolla; Laura Penta; Susanna Esposito
Journal:  Int J Environ Res Public Health       Date:  2017-09-10       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.